Cargando…

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1

This phase 2 study investigated long-term safety and efficacy of rilpivirine (RPV) plus two investigator-selected nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in HIV-1-infected antiviral therapy-naive adolescents. Participants (≥12 to <18 years of age) were treated with RPV at 25 mg onc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lombaard, Johan, Ssali, Francis, Thanyawee, Puthanakit, Fourie, Jan, Vanveggel, Simon, Linthicum, Cornelia, Van Eygen, Veerle, Van Solingen-Ristea, Rodica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Antiviral Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846324/ https://www.ncbi.nlm.nih.gov/pubmed/34871089 http://dx.doi.org/10.1128/aac.00916-21

Ejemplares similares

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine
por: Jeffrey, Jerry L., et al.
Publicado: (2022)

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection
por: Mehta, Rashmi, et al.
Publicado: (2018)

Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study
por: Steens, Jean-Marc, et al.
Publicado: (2017)

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
por: Underwood, Mark, et al.
Publicado: (2022)

Multipurpose Prevention Approaches with Antiretroviral-Based Formulations
por: Jean-Pierre, Ninochka, et al.
Publicado: (2016)

Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses
por: Ekins, Sean, et al.
Publicado: (2020)

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
por: Lawitz, Eric J., et al.
Publicado: (2016)

Antiviral Properties of HIV-1 Capsid Inhibitor GSK878
por: Wang, Chunfu, et al.
Publicado: (2023)

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
por: Badri, Prajakta S., et al.
Publicado: (2015)

Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs
por: Schooley, Robert T., et al.
Publicado: (2021)

Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals
por: de León, Patricia, et al.
Publicado: (2023)

Original Chemical Series of Pyrimidine Biosynthesis Inhibitors That Boost the Antiviral Interferon Response
por: Lucas-Hourani, Marianne, et al.
Publicado: (2017)

Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent
por: Xu, Yili, et al.
Publicado: (2021)

Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System
por: Moure, Ricardo, et al.
Publicado: (2018)

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
por: Jeon, Sangeun, et al.
Publicado: (2020)

A Photoactivable Natural Product with Broad Antiviral Activity against Enveloped Viruses, Including Highly Pathogenic Coronaviruses
por: Meunier, Thomas, et al.
Publicado: (2022)

Pharmacological Elevation of Cellular Dihydrosphingomyelin Provides a Novel Antiviral Strategy against West Nile Virus Infection
por: Jiménez de Oya, Nereida, et al.
Publicado: (2023)

PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy
por: Bekerman, Elena, et al.
Publicado: (2019)

Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model
por: Farooqui, Amber, et al.
Publicado: (2015)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir
por: Ng, Teresa I., et al.
Publicado: (2017)

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
por: Pitts, Jared, et al.
Publicado: (2022)

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
por: Tsiang, Manuel, et al.
Publicado: (2016)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
por: Ng, Teresa I., et al.
Publicado: (2017)

Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis
por: Berliba, Elina, et al.
Publicado: (2019)

Evaluation of in vitro antiviral activity of SARS-CoV-2 M(pro) inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions
por: Tong, Xiao, et al.
Publicado: (2023)

Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage
por: Nowicka-Sans, Beata, et al.
Publicado: (2016)

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
por: Painter, Wendy P., et al.
Publicado: (2021)

Lancemaside A from Codonopsis lanceolata: Studies on Antiviral Activity and Mechanism of Action against SARS-CoV-2 and Its Variants of Concern
por: Kim, Tai Young, et al.
Publicado: (2022)

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
por: Dieterich, Douglas, et al.
Publicado: (2014)

The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor
por: García-Nicolás, Obdulio, et al.
Publicado: (2018)

A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein
por: DeVincenzo, John, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2022)

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19
por: Good, Steven S., et al.
Publicado: (2021)

Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice
por: Melody, Kevin, et al.
Publicado: (2020)

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19
por: Doi, Yohei, et al.
Publicado: (2020)

Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells
por: Dinesh Kumar, Nilima, et al.
Publicado: (2022)

A truncated HIV Tat demonstrates potent and specific latency reversal activity
por: Van Gulck, Ellen, et al.
Publicado: (2023)

Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing
por: Innes, Steve, et al.
Publicado: (2018)

Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C
por: Ulferts, Rachel, et al.
Publicado: (2016)

Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial
por: Dong, Run, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tsjkidu8e6rp052o9c5i2r7n2n